Amgen announced that it commenced termination of a collaboration with AstraZeneca to develop brodalumab, a human IgG2 mAb targeting IL-17 receptor. Amgen recently presented data from three Phase 3 clinical trials evaluating brodalumab in patients with moderate-to-severe plaque psoriasis, and in connection with the presentation, suicidal ideation and completed suicides in the brodalumab program were noted. According to the company, the evidence to date does not suggest a causal association between IL-17 inhibition and suicidal ideation and behavior, but the events likely would necessitate restrictive labeling.
the official website of the antibody society
